Pharmasset, Inc. (Nasdaq: VRUS) announced today the pricing of an underwritten public offering of 3,300,000 shares of its common stock at an offering price of $46.33 per share. Of the shares being sold, Pharmasset is selling 2,300,000 shares and the selling stockholders are selling 1,000,000 shares. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $101.5 million. Pharmasset will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Pharmasset has granted the underwriters a 30-day option to purchase up to an additional 495,000 shares of common stock. The offering is expected to close on January 26, 2011, subject to customary closing conditions. Citi is serving as sole book-running manager for the offering. Morgan Stanley & Co. Incorporated is serving as the co-lead manager, and BofA Merrill Lynch, Leerink Swann LLC and Wedbush PacGrow Life Sciences are serving as co-managers.
The shares described above are being offered pursuant to an automatic shelf registration statement filed by Pharmasset with the Securities and Exchange Commission on January 18, 2011, which became effective upon filing.